玻璃体腔内注射抗VEGF药物治疗糖尿病视网膜病变效果观察

吴晓萍

（陕西西安市长安区人民医院，陕西 西安，710100）

浏览次数：90次 下载次数：369次

摘要：

目的 探讨玻璃体腔内注射抗内皮生长因子（VEGF）药物治疗糖尿病视网膜病变的临床效果。方法 选取我院2014年8月至2015年8月收治的糖尿病视网膜病变患者86例作为研究对象，所有患者均采用玻璃体腔内注射抗VEGF药物治疗， 观察患者治疗后的恢复情况。结果 治疗后，86例患者（132眼）临床有效率为90.15%。治疗后，患者的视力明显升高，眼压明显降低，与治疗前比较，差异具有统计学意义（P<0.05）。所有患者均无明显并发症发生。结论 玻璃体腔内注射抗VEGF药物治疗糖尿病视网膜病变患者临床效果显著，可推广使用。

关键词：糖尿病视网膜病变；玻璃体；血管内皮生长因子

中图分类号：R774.1；R587.2文献标志码：A文章编号：2096-1413(2017)19-0093-02

Effect observation of anti-VEGF drugs in the treatment of diabetic retinopathy by intravitreal injection
WU Xiao-ping
(Chang``an District People``s Hospital, Xi``an 710100, China)

ABSTRACT: Objective To investigate the clinical effect of anti-VEGF (vascular endothelial growth factor) drugs in the treatment of diabetic retinopathy by intravitreal injection. Methods Eighty-six patients with diabetic retinopathy admitted in our hospital from August 2014 to August 2015 were selected as the research objects. All the patients were treated with anti-VEGF drugs intravitreal injection, the recoveries of the patients after treatment were observed. Results The total effective rate in 86 patients with 132 eyes was 90.15 %. After treatment, the visual acuity of the patients significantly increased, and the intraocular pressure significantly decreased, the differences were statistically significant (P<0.05). There was no obvious complication. Conclusion Anti-VEGF drug in the treatment of diabetic retinopathy by intravitreal injection has significant clinical effect, which can be widely used in clinic.
KEYWORDS: diabetic retinopathy; vitrectomy; vascular endothelial growth factor

参考文献：
[1] 朱小丽.玻璃体腔注射抗VEGF 药物治疗糖尿病视网膜病变的相关指标观察[J].现代诊断与治疗,2015,26(13):3080-3081.
[2] 余萍.术前玻璃体腔内注射抗VEGF 对增殖性糖尿病性视网膜病变行玻璃体术的影响研究[J].高原医学杂志,2015,25(4):21-24.
[3] 宋艳萍,黄志坚,丁琴,等.光动力疗法联合玻璃体腔注射抗VEGF药物治疗中心性渗出性脉络膜视网膜病变的临床观察[J].中国激光医学杂志,2010,28(6):259-261.
[4] MONTERO JA,RUIZ-MORENO JM,CORREA ME.Intravitreal anti-VEGF drugs as adjuvant therapy in diabetic retinopathy surgery[J].Curr Diabetes Rev,2011,7(3):176-184.
[5] 王德功.玻璃体腔注射ranibizumab 辅助微创玻璃体视网膜手术治疗严重增生型糖尿病视网膜病变的临床观察[D].天津:天津医科大学,2014.
[6] 王友,邓铂林,黄健,等.玻璃体腔注射雷珠单抗治疗严重增生型糖尿病视网膜病变后玻璃体细胞因子的变化[J].中华眼底病杂志,2014,30(5):484-487.
[7] 朱丽,陈晓,宋艳萍,等.玻璃体腔注射雷珠单抗联合25G 玻璃体视网膜手术治疗增生型糖尿病视网膜病变的临床观察[J].中华眼底病杂志,2016,32(1):22-25.
[8] 冯萧萧,肖丽波,胡竹林,等.单纯23G 玻璃体切割手术与玻璃体腔注射抗血管内皮生长因子单克隆抗体ranibizumab 联合23G 玻璃体切割手术治疗增生型糖尿病视网膜病变对比观察[J].中华眼底病杂 志,2014,30(2):193-194.
[9] 李涛,郑志,郑冰清,等.贝伐单抗辅助的23G 玻璃体切割术治疗严重增生性糖尿病视网膜病变的疗效观察[J].现代生物医学进展,2013,13(23):4488-4491.
[10] 陈世久,秦梅.糖尿病视网膜病变联合玻璃体腔药物注射治疗新进展[J].医学综述,2015,21(17):3188-3191.